{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:26:07Z","timestamp":1783992367399,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008296","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T00:00:00Z","timestamp":1339545600000}}],"reference-count":80,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008296.pub2","type":"journal-article","created":{"date-parts":[[2012,6,8]],"date-time":"2012-06-08T15:06:11Z","timestamp":1339167971000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Paliperidone palmitate for schizophrenia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Abraham M","family":"Nussbaum","sequence":"first","affiliation":[{"name":"Denver Health; Behavioural Health Service; MC 0490 777 Bannock Street Denver CO USA 80204"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T S","family":"Stroup","sequence":"additional","affiliation":[{"name":"Columbia University; Psychiatry; 1051 Riverside Drive Room 2703, Box 100 New York New York USA 10032"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,13]]},"reference":[{"key":"10.1002\/14651858.CD008296.pub2-BIB0001|cit1","unstructured":"Johnson and Johnson Pharmaceutical Research and Development LLC A randomized, double blind, parallel group, comparative study of flexibly dosed paliperidone palmitate (25, 50, 75, or 100 mg eq.) administered every 4 weeks and flexibly dosed risperdal consta (25, 37.5, or 50 mg) administered every 2 weeks in subjects with schizophrenia http:\/\/www.clinicaltrials.gov 2005"},{"issue":"5","key":"10.1002\/14651858.CD008296.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0003|cit3","unstructured":"Johnson & Johnson Pharmaceutical Research & Development LLC A randomized, double blind, placebo-controlled, parallel-group, dose-response study to evaluate the efficacy andsafety of 3 fixed doses (50 mg eq, 100 mg eq, and 150 mg eq) of paliperidone palmitate in subjects with schizophrenia http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0004|cit4","unstructured":"Hough D Gopal S Vijapurkar U Lim P Morozova M Eerdekens M Paliperidone palmitate, an atypical injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, doubleblind, placebo-controlled study Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0005|cit5","unstructured":"Hough D Gopal S Vijapurkar U Lim P Morozova M Eerdekens M Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study Biological Psychiatry 2008 285S 6S"},{"issue":"2-3","key":"10.1002\/14651858.CD008296.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0007|cit7","unstructured":"Kramer M Litman R Hough D Lane R Lim P Eerdekens M A 9-week, placebo-controlled study in schizophrenia patients: efficacy and safety of the long-acting injectable agent, paliperidone palmitate Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"issue":"5","key":"10.1002\/14651858.CD008296.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","article-title":"Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study","volume":"13","author":"Kramer","year":"2009","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2007.12.389","article-title":"Efficacy\/tolerability of paliperidone palmitate: 9-week, placebo-controlled study in schizophrenia patients","volume":"98","author":"Kramer","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0010|cit10","first-page":"288S","article-title":"Efficacy and tolerability of paliperidone palmitate: 9-week, placebo-controlled study in schizophrenia patients","volume":"63","author":"Kramer","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD008296.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/npp.2010.79.","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0012|cit12","unstructured":"Nasrallah HA Gopal S Gassmann-Mayer C Quiroz JA Lim P Eerdekens M Efficacy and safety of three doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic in schizophrenia Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0013|cit13","unstructured":"Fleischhacker WW Gopal S Samtani MN Quiroz JA Pandina G Vermeulen A Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharmacokinetic simulations Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0014|cit14","unstructured":"Fleischhacker WW Gopal S Samtani MN Quiroz JA Pandina G Vermeulen A Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharmacokinetic simulations Proceedings of the 47th Annual meeting of the American College of Neuropsychopharmacology; 2008 Dec 7-11; San Francisco, CA 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0015|cit15","unstructured":"Haskins JT Sliwa JK Ma Y-W Pandina GJ Palumbo J Efficacy and safety of 234 mg initiation dose and 3-fixed maintenance doses of paliperidone palmitate\u2014a once-monthly injectable atypical antipsychotic Proceedings of the U.S. Psychiatric and Mental Health Congress; 2009 November 2-5; Las Vegas, Nevada 2009"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0016|cit16","unstructured":"Pandina GJ Lindenmayer J-P Lull J Lim P Gopal S Herben V A randomized, double-blind, placebo-controlled, dose-response efficacy and safety study of paliperidone palmitate in adults with schizophrenia Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"issue":"3","key":"10.1002\/14651858.CD008296.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0018|cit18","unstructured":"Pandina GJ Lindenmayer JP Lull J Lim P Gopal S Kusumakar V A randomized, placebo-controlled study to assess the efficacy and safety of three doses of paliperidone palmitate in adults with an acute exacerbation of schizophrenia Proceedings of the College of Psychiatric and Neurologic Pharmacists Annual General Meeting; 2009 April 19-22; Jacksonville, Florida 2009"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0019|cit19","unstructured":"Fleischhacker WW Gopal S Samtani MN Quiroz JA Pandina G Vermeulen A Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA 2009"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0020|cit20","unstructured":"Fleischhacker WW Gopal S Samtani MN Quiroz JA Pandina G Vermeulen A Optimization of the dosing strategy for the long-acting injectable antipsychotic paliperidone palmitate: results of two randomized double-blind studies and population pharmacokinetic simulations Proceedings of the 47th Annual meeting of the American College of Neuropsychopharmacology; 2008 Dec 7-11; San Francisco, CA 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0021|cit21","unstructured":"Johnson & Johnson Pharmaceutical Research and Development LLC Comparison ofpaliperidone palmitate and risperdal consta in patients with schizophrenia http:\/\/www.clinicaltrials.gov"},{"issue":"1","key":"10.1002\/14651858.CD008296.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0023|cit23","unstructured":"Cleton A Rossenu S Crauwels Berwaerts J Hough D Gopal S Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic, following administration in the deltoid or gluteal muscles Proceedings of the Institute of Psychiatric Services; 2008 October 2-5; Chicago, Illinois 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0024|cit24","unstructured":"Cleton A Rossenu S Hough D Crauwels H Vandebosch A Berwaerts J Evaluation of the pharmacokinetic profile of deltoid versus gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia Institute of Psychiatric Services Chicago, Illinois, USA"},{"issue":"5","key":"10.1002\/14651858.CD008296.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0269881110372817","article-title":"A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia","volume":"25","author":"Gopal","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0026|cit26","unstructured":"Gopal S Lindenmayer JP Hough D Melkote R Lim P Herben V Safety and tolerability of the investigational antipsychotic paliperidone palmitate injected in the deltoid or gluteus muscle in patients with schizophrenia Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0027|cit27","unstructured":"Gopal S Lindenmayer JP Hough D Melkote R Lim P Yuen E Safety and Tolerability Profiles of Paliperidone Palmitate Injected in Either the Deltoid or Gluteus Muscle in Patients with Schizophrenia Proceedings of the Institute of Psychiatric Services; 2008 October 2-5; Chicago, IL 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":"Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia","volume":"33","author":"Hough","year":"2009","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0029|cit29","unstructured":"Johnson & Johnson Pharmaceutical Research & Development LLC Pharmacokinetics,tolerability, and safety of intramuscular injections of paliperidone palmitate in the arm or buttock of subjects with schizophrenia http:\/\/www.clinicaltrials.gov 2003"},{"issue":"4","key":"10.1002\/14651858.CD008296.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0031|cit31","unstructured":"Tan Q Shi J Li Kq Comparative study of paliperidone palmitate (50, 100, 150 mg eq) and risperidone LAI (long acting injection) (25, 37.5, or 50 mg) in patients with schizophrenia http:\/\/www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0032|cit32","unstructured":"Ortho-McNeil Janssen Scientific Affairs LLC 28-30 month study comparing paliperidone palmitate with oral risperidone for treating adults diagnosed with schizophrenia within the past 5 years http:\/\/www.clinicaltrials.gov 2009"},{"issue":"1","key":"10.1002\/14651858.CD008296.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/157488611794480070","article-title":"Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium\/sedation syndrome? an assessment of safety databases","volume":"6","author":"Alphs","year":"2010","journal-title":"Current Drug Safety"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1744-859X-10-12","article-title":"Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial","volume":"10","author":"Alphs","year":"2011","journal-title":"Annals of General Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"1324","key":"10.1002\/14651858.CD008296.pub2-BIB0036|cit36","first-page":"88","article-title":"In brief: injectable paliperidone palmitate for schizophrenia","volume":"51","author":"Anon","year":"2009","journal-title":"Medical Letter"},{"issue":"3","key":"10.1002\/14651858.CD008296.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4088\/JCP.v67n0317","article-title":"Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care","volume":"67","author":"Ascher-Svanum","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD008296.pub2-BIB0040|cit40","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-244X-11-79","article-title":"Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial","volume":"11","author":"Bossie","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0042|cit42","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD008296.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008296.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD008296.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0091270009350622","article-title":"Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration","volume":"50","author":"Elliott","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Supplement","key":"10.1002\/14651858.CD008296.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1192\/bjp.195.52.s29","article-title":"Second-generation antipsychotic long-acting injections: systematic review","volume":"52","author":"Fleischhacker","year":"2009","journal-title":"British Journal of Psychiatry"},{"issue":"18","key":"10.1002\/14651858.CD008296.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008296.pub2-BIB0050|cit50","first-page":"288","article-title":"Reliability, validity and sensitivity to change of the personal and social performance scale in patients with stable schizophrenia","volume":"9","author":"Gagnon","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/NDT.S17177","article-title":"Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia","volume":"8","author":"Gopal","year":"2011","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: Data from the health survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0053|cit53","volume-title":"Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0054|cit54","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD008296.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004161","article-title":"Depot risperidone for schizophrenia","author":"Hosalli","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008296.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/11203810-000000000-00000","article-title":"Intramuscular paliperidone palmitate","volume":"24","author":"Hoy","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD008296.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0058|cit58","unstructured":"Janssen Pharmaceutica Products LP Risperdal consta (risperidone) long-acting injection prescribing information Janssen Pharmaceutica Products, L.P. 2003"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0059|cit59","unstructured":"Janssen Pharmaceutica Products LP Invega (paliperidone) extended-release tablets prescribing information Janssen Pharmaceutica Products, L.P. 2006"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0060|cit60","unstructured":"Janssen Invega Sustenna (paliperidone palmitate) extended-release injectable suspension prescribing information Orth-McNeil-Janssen Pharmaceuticals, Inc. 2009"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0061|cit61","unstructured":"Janssen-Cilag Ltd Risperidal (risperidone) summary of product characteristics UK: Janssen-Cilag Ltd 1996"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0062|cit62","volume-title":"The positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"issue":"8","key":"10.1002\/14651858.CD008296.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1185\/03007995.2011.595000","article-title":"Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)","volume":"27","author":"Kozma","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"2-3","key":"10.1002\/14651858.CD008296.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD008296.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0067|cit67","volume-title":"The American Psychiatric Publishing Textbook of Schizophrenia","author":"Lieberman","year":"2006"},{"issue":"12","key":"10.1002\/14651858.CD008296.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD008296.pub2-BIB0070|cit70","first-page":"15","article-title":"Risks versus benefits of different types of long-acting injectable antipsychotics","volume":"67","author":"McEvoy","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD008296.pub2-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006369.pub2","article-title":"Oral paliperidone for schizophrenia","author":"Nussbaum","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008296.pub2-BIB0074|cit74","first-page":"S287","article-title":"Reliability, validity and sensitivity to change of the personal and social performance scale in patients with acute schizophrenia","volume":"9","author":"Patrick","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008296.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1185\/03007990802611919","article-title":"Reliability, validity and ability to detect change of the clinician-rated personal and social performance scale in patients with acute symptoms of schizophrenia","volume":"25","author":"Patrick","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0076|cit76","unstructured":"Samtani MN Gopal S Sliwa JK Haskins JT Alphs L Stuyckens Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulation Proceedings of the 49th NCDEU: New Research Approaches for Mental Health Interventions; 2009 June 29- July 2; Hollywood, Florida 2009"},{"issue":"9","key":"10.1002\/14651858.CD008296.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia","volume":"48","author":"Samtani","year":"2009","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0078|cit78","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD008296.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD008296.pub2-BIB0080|cit80","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo 2007"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008296.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:06:33Z","timestamp":1749427593000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008296.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,13]]},"references-count":80,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008296.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,13]]}}}